Media About Us

Proteon Pharmaceuticals is Fighting Salmonella by Attacking it on the Farm

Proteon Pharmaceuticals COO Matthew Tebeau sat down with Christine Corrado from Proactive Investors at the 11th Annual BioTech Showcase in San Francisco.

The Poland-based biotech aims to reduce reliance on antibiotics by using naturally-occurring bacteriophages to prevent and treat infectious diseases.



Proteon Pharmaceuticals Joins Research Efforts to Fight Coronavirus

In response to the fight against coronavirus, Proteon Pharmaceuticals has joined the effort to create a new SARS-CoV-2 Coronavirus Detection Center in Lodz, Poland to conduct large-scale tests for virus diagnosis. The new laboratory was created at a very fast pace with the involvement and cooperation of the Institute of Medical Biology of the Polish Academy of Sciences, the University of Lodz, the Medical University of Lodz.  It is staffed by a team of microbiologists, geneticists, doctors and experts, including scientists from biotechnology company Proteon Pharmaceuticals. The goal is to conduct as many tests as possible in the shortest possible time. 



13.12.2017, Polish company seeks to take bacteriophages to the global market (

Developing a bacteriophage platform technology for use in animal health has taken Polish company Proteon Pharmaceuticals a decade to master. Chief operating officer Mathew Tebeau talks to Animal Pharm analyst
Malcolm Flanagan about the firm's past and future.


9.11.2017, Aqua-Spark feeding sustainable aquaculture movement with keystone investments (

Netherlands-based investment fund Aqua-Spark is feeding the growth of the sustainable aquaculture movement with an increasingly large and diverse portfolio of investments in the sector.


3.11.2017, Aqua-Spark backs aquaculture ventures Proteon Pharmaceuticals and Cryoocyte (

The Dutch aquaculture fund has made 15 sustainable aquaculture investments over the last two years.

Poland-based Proteon has developed an antibiotic-free method of killing bacteria like salmonella in fish and poultry.


30.10.2017, Aqua-Spark broadens investment scope with two aqua-tech investments (

Dutch, pure-play sustainable aquaculture investment fund Aqua-Spark has made two investments that broaden its reach into technologies that have the potential to reduce the use of antibiotics in animal protein production, and to advance fish breeding methodology.


26.10.2017, Aquaculture Fund Aqua-Spark Moves Beyond Farms and Feed With Two New Investments (

Aqua-Spark, the Dutch venture capital fund, has finalized two investments this week that signal the fund dedicated to the future of aquaculture is moving beyond farms and feed.

The new investments are in two animal health startups Proteon Pharmaceuticals and Cryoocyte.

Read more >> 

25.10.2017, Aqua Spark invests in technology to boost aquaculture (

Investment fund Aqua-Spark has announced its latest investments to radically improve fish farming by eliminating antibiotics, reducing feed, and enabling farms to safeguard their broodstock.


24.10.2017, Aqua-Spark invests in fish farming technologies (
23.10.2017, Fresh funding for biotech firms (

Two fledgling biotech firms, one of which uses cutting edge technology to eliminate antibiotic use in fish farming and the other improves fish genetics, have secured investments this week.

The support for the companies, Proteon Pharmaceuticals and Cryoocyte, comes from Aqua-Spark, the first investment fund focused exclusively on sustainable aquaculture.


Our Solutions

Contact Proteon